NCT06578624: An ongoing trial by Lamassu Bio Inc
This trial is ongoing. It must report results 12 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06578624 |
|---|---|
| Title | A Phase 1/2a, Open-Label Study of Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SA53-OS, an MDM2 Inhibitor, in Patients With Locally Advanced or Metastatic p53 Wild-Type Solid Tumors |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 10, 2025 |
| Completion date | March 31, 2026 |
| Required reporting date | March 31, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |